1. Turnaround Story of Denny�� (DENN): Denny�� owns and is a franchiser of family diners. The company controls about 9% of the family dining market and competes directly with IHOP which controls 11%.
When you look at the fundamental numbers, it doesn�� look like a value play. However, over the past few years, Denny�� is focusing on paying back debt and buying back shares.
Revenues have declined every year since 2006, but interestingly, gross margins have gone up from 18.5% from 2006 to 29% TTM. This margin expansion has traveled all the way down to the bottom line because Denny�� is FCF positive and 2011 and 2012 were stellar years in terms of FCF.
The TTM figures looks to be slightly less than 2012 FCF of $45 million, but in their situation, this year will be another successful and FCF-positive year.
Looks like Denny�� has been putting all that free cash flow to good use as well.
Since 2008, long-term debt has been reduced by almost 50% TTMShares outstanding has decreased 7% from 2010Another interesting piece is that 2013 may be the year where shareholder equity reaches positive territory for the first time in more than 10 years.
Hot Wireless Telecom Companies For 2015: Lam Research Corporation(LRCX)
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipments used in the fabrication of integrated circuits. The company offers etch products that remove portions of various films from the wafer in the creation of semiconductor devices. Its etch products include dielectric etch, conductor etch, three-dimensional integrated circuit etch, MEMS devices, CMOS image sensors, and power devices for etching process. Lam Research Corporation also provides wafer cleaning steps that comprise post-etch and post-strip cleans, and pre-diffusion and pre-deposition cleans; and single-wafer wet clean and plasma-based bevel clean systems. The company offers its products to semiconductor manufacturers. It operates in the United States, Europe, Taiwan, Korea, Japan, and the Asia Pacific. Lam Research Corporation was founded in 1980 and is headquartered in Fremont, California.
Advisors' Opinion:- [By Markus Aarnio]
Lam Research Corporation (LRCX) designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits.
- [By Ben Levisohn]
Companies that could benefit from a pickup in capital spending include Akamai Technologies (AKAM) and priceline.com (PCLN), which have the highest sensitivity to “non-residential fixed investment in Intellectual Property Products,” Frontier Communications (FTR) and Lam Research (LRCX), which have the highest sales sensitivity to non-residential fixed investment in Equipment,” and Transocean (RIG), which is among the companies with a high exposure to “non-residential fixed investment in Structures.”
- [By Sue Chang and Saumya Vaishampayan]
$KLAC: KLA-Tencor Corp. (KLAC) �shares rose 1.9%. Analysts at J.P. Morgan on Monday initiated coverage of KLA-Tencor and Lam Research Corp. (LRCX) �at overweight.
Best Up And Coming Companies To Invest In 2014: Interpublic Group of Companies Inc (IPG)
The Interpublic Group of Companies, Inc. (Interpublic), incorporated in September 1930, is a global advertising and marketing services companies. Interpublic�� companies specialize in consumer advertising, digital marketing, communications planning and media buying, public relations and specialized communications disciplines. The Company has two segments: Integrated Agency Networks (IAN) and Constituency Management Group (CMG). IAN is comprised of McCann, Draftfcb, Lowe, Mediabrands and its domestic integrated agencies. CMG is comprised of a number of its specialist marketing services offerings. During the year ended December, 31, 2011, it completed 22 acquisitions, which included purchases of controlling interests in previously unconsolidated subsidiaries. Of these acquisitions, 18 are included in IAN operating segment and four are included in CMG operating segment. All acquired agencies have been integrated into one of its global networks or existing agencies. The acquisitions included service creative agencies in Australia, a public relations firm in Brazil, digital and direct marketing agencies in the United Kingdom, a healthcare communications firm in Germany and a social media agency in the United States. In November 2013, Interpublic Group of Companies Inc's MRM, a global digital and direct agency within McCann Worldgroup, a unit of the Interpublic Group of Companies, acquired the Brazilian agency E/OU. In January 2014, Interpublic Group of Companies Inc announced that its division Lowe and Partners, announced the acquisition of the global digital network Profero.
The Company�� agencies create customized marketing programs for companies. The Company has three global networks: McCann Worldgroup (McCann); Draftfcb and Lowe & Partners (Lowe), that provide integrated, advertising and marketing solutions for clients, and two global media services companies, UM and Initiative, operating under the Mediabrands umbrella. It premier also has domestic integrated and interactive agencies. ! Its solutions vary from project-based activity involving one agency to long-term, integrated campaigns created by multiple IPG agencies working together.
McCann offers a range of communications tools and resources to companies and brands. McCann Erickson Advertising has operations in over 100 countries. MRM Worldwide is its global digital and customer relationship management (CRM) network. Momentum Worldwide is engaged in experiential marketing and promotions, as is McCann Healthcare Worldwide in healthcare communications. Draftfcb is an agency model for clients seeking creative and accountable marketing programs delivered in a media-neutral manner under a unified, integrated business.
Lowe is a creative agency. Lowe is developing ideas that connect with culture. Mediabrands delivers on the scale and breadth of its media capabilities. UM and Initiative seek to deliver business results by advising clients on how to navigate an increasingly complex and digital marketing landscape. Specialist brands within Mediabrands focus on areas, such as the targeting and aggregation of audiences in the digital space, hyper-local marketing, media barter and a range of other capabilities.
The Company�� domestic integrated independent agencies include agency brands, including Campbell-Ewald, Hill Holliday, The Martin Agency and Mullen. The marketing programs created by the group incorporate all media channels, CRM, public relations and other marketing activities and have helped build some of the brands in the United States, across all sectors and industries. It has marketing specialists across a range of disciplines. These include Jack Morton (experiential marketing), Octagon (sports marketing), public relations agencies, such as Weber Shandwick and GolinHarris, FutureBrand (corporate branding), and its digital specialist agencies, led by R/GA and HUGE. Its healthcare communications specialists reside within its three global brands: McCann, Draftfcb and Lowe.
Advisors' Opinion:- [By Rich Smith]
On a relatively slow day for Defense Department business Tuesday, a sizable contract was awarded to a company you don't often think of as belonging to the military-industrial complex: McCann Worldgroup, a subsidiary of giant, globetrotting ad agency Interpublic (NYSE: IPG ) � -- and just in time for the return of Mad Men.
- [By Jayson Derrick]
Elliot Management disclosed a 6.7 percent stake in Interpublic Group (NYSE: IPG) and intends to push the came to sell itself. Shares gained 1.51 percent, closing at $20.15.
- [By Lee Jackson]
The Interpublic Group of Companies Inc. (NYSE: IPG) is an interesting name to attend. Formerly known as monster advertising agency McCann-Erickson, it is an integral cog in the entertainment and media machine. The consensus price target is $17.20. Investors receive a 1.7% dividend.
Best Up And Coming Companies To Invest In 2014: Guided Therapeutics Inc (GTHP)
Guided Therapeutics, Inc., incorporated on October 27, 1992, is a medical technology company focused on developing medical devices. The Company�� primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.
The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. The product is expected to incorporate a single-use, disposable calibration and alignment component.
The Company competes with Qiagen, MediSpectra, Inc., Merck & Co., Inc., and GlaxoSmithKline PLC.
Advisors' Opinion:- [By CRWE]
Today, GTHP remains (0.00%) +0.000 at $.710 with 44,700 shares in play thus far (ref. google finance Delayed: 11:42AM EDT August 21, 2013).
Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.
Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.
- [By CRWE]
Last Friday, GTHP had shed (-2.16%) down -0.015 at $.679 with 39,538 shares in play at the close (ref. google finance August 23, 2013 ��Close).
Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.
Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.
Best Up And Coming Companies To Invest In 2014: Orexigen Therapeutics Inc.(OREX)
Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed phase III clinical trials; and Empatic that has completed phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; and naltrexone is a treatment for alcohol and opioid addiction. The company?s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide is for the adjunctive treatment of partial seizures, a form of epilepsy. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave. Orexigen Therapeutics, Inc. was founded in 2002 and is based in La Jolla, California.
Advisors' Opinion:- [By Ben Levisohn]
Vivus (VVUS) has gained 4.3% to $10.63 after Cowen upgraded it to Outperform from Hold, and Orexigen Therapeutics (OREX) rose 4% to $6.30 after Cowen started it as Outperform.
Best Up And Coming Companies To Invest In 2014: Global Digital Creations Holdings Ltd (GDC)
Global Digital Creations Holdings Limited is an investment holding company. Through its subsidiaries, the Company operates in three segments: computer graphics (CG) and production segment, which includes CG creation, production and exhibition of motion pictures and production of television series and movies, as well as property rental income; CG training courses segment, engaged in the provision of CG and animation training, and cultural park segment, engaged in the media entertainment and related commercial property development. The Company�� subsidiaries include GDC Holdings Limited, GDC Asset Management Limited, GDC China Limited, GDC Digital Cinema Network Limited, GDC Digital Cinema Network Limited, GDC International Limited and GDC Management Services Limited, among others. On September 6, 2011, it completed the disposal of interests in GDC Technology Limited and GDC Digital Cinema Network Limited. Advisors' Opinion:- [By Barel Karsan]
If you follow Genesis Land (GDC), your head may be spinning by now. It's almost every day now that the current board and the activists trying to take it over are claiming some sort of injustice permeated by the other side. (To watch this battle in real-time, sign up for filing notifications for GDC here.) But surely, behind all the "Our directors are superior to yours" puffery, there are some differences in how each group would run the company differently.
No comments:
Post a Comment